Adjuvant chemotherapy after pancreatic cancer resection can improve patient survival, but the optimal treatment cycle and timing of chemotherapy initiation are unknown. valle and his colleagues conducted a retrospective analysis of the European Pancreatic Cancer Study Group’s phase III ESPAC-3 trial on these issues. Overall survival was significantly better in patients who were treated with six courses of chemotherapy. The median overall survival was 28 months for patients who completed all courses of therapy and 14.6 months for those who did not. The timing of adjuvant chemotherapy initiation did not have an impact on overall survival compared to other tumors. In other solid tumors, particularly colorectal cancer, the timing of chemotherapy initiation is very important: for every 4-week delay in the timing of adjuvant therapy, survival decreases significantly. This retrospective analysis suggests that this does not apply to pancreatic cancer, and perhaps clinicians should ensure that patients are healthy enough to complete the full course of chemotherapy rather than rushing to start adjuvant chemotherapy. This is illustrated by the difference in survival between patients who completed all 6 courses of therapy and those who did not.